Immunocore Holdings plc

Immunocore is a commercial-stage biotechnology company developing immunotherapies for cancer, infectious diseases, and autoimmune conditions. The company's marketed product is KIMMTRAK, approved for patients with unresectable or metastatic uveal melanoma. Its clinical pipeline includes multiple programs in Phase 1 through Phase 3 trials, spanning oncology indications such as advanced cutaneous melanoma and solid tumors, as well as infectious disease candidates targeting HIV and hepatitis B virus that aim to achieve functional cures. Earlier-stage programs address type 1 diabetes and atopic dermatitis.

The company's revenue derives from KIMMTRAK sales, with additional value from its clinical and preclinical pipeline. Key clinical assets include tebentafusp and brenetafusp, both in Phase 3 trials for melanoma indications, and multiple first-in-class programs based on the company's proprietary Gag-Engineered T-cell Receptor (GE-TCR) platform technology.

Immunocore operates with approximately 493 full-time employees and is headquartered in Abingdon, United Kingdom. The company is incorporated in the United Kingdom and listed on Nasdaq, with a market capitalization of $1.7 billion.